Fubotv earnings beat by $0.10, revenue topped estimates
LONDON - CRISM Therapeutics Corporation (AIM:CRTX), a UK-based drug delivery company, has been awarded the Drug Delivery and Translational Research Journal Outstanding Paper Award by the Controlled Release Society (CRS). The company’s research on ChemoSeed, a local chemotherapy delivery technology, earned the accolade for its potential to improve treatment for glioblastoma, a type of brain cancer.
The awarded paper, titled "Local administration of irinotecan using an implantable drug delivery device stops high-grade glioma tumour recurrence in a glioblastoma tumour model," was recognized for its impact and innovation in the field of drug delivery. The study presents the preclinical validation of ChemoSeed, which is designed to enhance the precision of chemotherapy by delivering drugs directly to the tumor site, thereby reducing systemic toxicity.
Prof. Chris McConville, Chief Scientific Officer at CRISM and lead author of the paper, expressed gratitude for the recognition, noting it as a strong third-party endorsement of the technology’s scientific foundation. The award will be presented at the CRS Annual Meeting in Philadelphia, PA, in July 2025.
The achievement underscores CRISM’s commitment to developing safer and more efficacious therapies for solid tumors. The information about this award is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.